Skip to main content
. Author manuscript; available in PMC: 2012 May 30.
Published in final edited form as: Mar Biotechnol (NY). 2010 Mar 28;13(2):142–150. doi: 10.1007/s10126-010-9274-2

Table 1.

Tumor incidence in control and transgenic zebrafish

Treatment group Fraction of fish with
histologic tumors (%)		 Tumor histologic types Sex ratio M/
total (%M)
Control (3 year) 0/11 (0%) None 6/11 (54%)
Krt8-GFP and CMVtk rv-cyclin (3 years) 0/14 (0%) None 7/14 (50%)
Krt8-GFP and CMVtk rv-cyclin ENU-treated (2 years) 3/20 (15%) 2/20 spermatocytic seminomas of testis; 1/20 malignant peripheral nerve-sheath tumor of gas bladder and ovary 14/20 (70%)
Krt8-GFP ENU-treated (2 years) 2/13 (15%) 2/13 spermatocytic seminomas of testis 11/13 (85%)
Control zebrafish ENU-treated (2 years) 1/22 (5%) 1/22 hepatocellular adenoma 11/22 (50%)
Krt8-GFP tail regeneration (1 year) 0/16 (0%) None 8/16 (50%)
CMVtk rv-cyclin tail regeneration (1 year) 0/16 (0%) None 8/16 (50%)